(3-氧代-2,3-二氢-4H-1,4-苯并恶嗪)-4-乙酸 | 26494-55-3

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: (3-氧代-2,3-二氢-4H-1,4-苯并恶嗪)-4-乙酸
• 中文别名: (3-氧代-2,3-二氢-4H-1,4-苯并噁嗪-4-基)乙酸；2,3-二氢-3-羰基-4H-1,4-苯并恶嗪)-4-乙酸
• 英文名称: 2-(3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)acetic acid
• 英文别名: 2-(3-oxo-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)acetic acid；(3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetic acid；2-(3-oxo-1,4-benzoxazin-4-yl)acetic acid
• CAS: 26494-55-3
• 化学式: C₁₀H₉NO₄
• mdl: MFCD00269587
• 分子量: 207.186
• InChiKey: POGLODLVBYOXAO-UHFFFAOYSA-N

物化性质

• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，请避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
(3-Oxo-2,3-dihydro-4h-1,4-benzoxazin-4-yl)acetic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
(3-Oxo-2,3-dihydro-4h-1,4-benzoxazin-4-yl)acetic acid
Ingredient name:
CAS number: 26494-55-3

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H9NO4
Molecular weight: 207.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (3-氧代-2,3-二氢-4H-1,4-苯并恶嗪)-4-乙酸 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 4-(2-(3-oxo-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)acetyl)-N-phenylpiperazine-1-carboxamide
  参考文献：
  名称：

  苯并[b] [1,4]恶嗪-3（4H）-one作为分支杆菌胸苷酸合酶X抑制剂的类似物的合成及构效关系研究。

  摘要：

  由于发现了人类中不存在的黄素依赖性胸苷酸合酶（ThyX或FDTS），但对于多种病原体中的DNA生物合成至关重要，该酶一直被用于开发针对结核分枝杆菌的新型抗菌剂。广泛的传染病结核病（TB）的病原体。为了响应对更有效的抗结核药物的日益增长的需求，我们在之前的筛选工作基础上，在此报告了一系列具有独特抑制谱的新型抑制剂的优化方案。抑制剂对ThyX的亚甲基四氢叶酸辅因子表现出竞争性抑制作用，使我们能够生成与目标结合的化合物模型，从而深入了解其结构与活性之间的关系。

  DOI：

  10.1002/cmdc.201800739
• 作为产物：
  描述：

  methyl 2-(3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetate 在 甲醇 、 sodium hydroxide 、 水 、 盐酸 作用下， 反应 3.5h， 生成 (3-氧代-2,3-二氢-4H-1,4-苯并恶嗪)-4-乙酸
  参考文献：
  名称：

  Carboxylic Acid Compounds and Use Thereof

  摘要：

  提供一种优越的URAT1活性抑制剂，用于治疗与尿酸有关的病理，如高尿酸血症、痛风石、急性痛风性关节炎、慢性痛风性关节炎、痛风性肾病、尿路结石、肾功能障碍、冠心病、缺血性心脏病等。 一种包含下式[1]所表示的化合物或其药学上可接受的盐，或其溶剂化合物的URAT1活性抑制剂作为活性成分： 其中每个符号如规范中定义。

  公开号：

  US20070197512A1

文献信息

• [EN] COMPOUNDS USEFUL AS CSF1 MODULATORS<br/>[FR] COMPOSÉS UTILES EN TANT QUE MODULATEURS DU FACTEUR 1 DE STIMULATION DE COLONIES
  申请人：REDX PHARMA PLC

  公开号：WO2016051193A1

  公开（公告）日：2016-04-07

  This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.

  这项发明涉及新颖化合物以及包含这些新颖化合物的药物组合物。更具体地，该发明涉及用作集落刺激因子1受体（cFMS）调节剂（例如cFMS抑制剂）的化合物。这项发明还涉及制备这些化合物的方法，这些化合物在治疗中的用途以及利用这些化合物进行治疗的方法。具体而言，该发明涉及利用这些化合物治疗癌症和自身免疫性疾病。
• Carboxylic Acid Compounds and Use Thereof
  申请人：Inoue Teruhiko

  公开号：US20070197512A1

  公开（公告）日：2007-08-23

  Provision of a superior URAT1 activity inhibitor effective for the treatment and the like of a pathology involving uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urinary lithiasis, renal dysfunction, coronary heart disease, ischemic cardiac diseases and the like. A URAT1 activity inhibitor containing a compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient: wherein each symbol is as defined in the specification.

  提供一种优越的URAT1活性抑制剂，用于治疗与尿酸有关的病理，如高尿酸血症、痛风石、急性痛风性关节炎、慢性痛风性关节炎、痛风性肾病、尿路结石、肾功能障碍、冠心病、缺血性心脏病等。 一种包含下式[1]所表示的化合物或其药学上可接受的盐，或其溶剂化合物的URAT1活性抑制剂作为活性成分： 其中每个符号如规范中定义。
• Design, Synthesis, and Evaluation of the Kinase Inhibition Potential of Pyridylpyrimidinylaminophenyl Derivatives
  作者：Priyanka Manchanda、Badri Parshad、Amit Kumar、Rakesh K. Tiwari、Amir N. Shirazi、Keykavous Parang、Sunil K. Sharma

  DOI：10.1002/ardp.201600390

  日期：2017.4

  of myriad human disorders, we synthesized some structurally variant amide/cyclic amide derivatives based on pyridylpyrimidinylaminophenyl amine, the key pharmacophore of the kinase inhibitor drug molecule, imatinib, and evaluated their kinase inhibition potency. Among the various synthesized amides, compound 20, a cyclic amide/pyridin‐2(1H)‐one derivative, exhibited an IC50 value comparable to that

  鉴于用于治疗多种人类疾病的有效激酶抑制剂，我们合成了一些基于吡啶基嘧啶基氨基苯胺（激酶抑制剂药物分子伊马替尼的关键药效​​团）的结构变异酰胺/环酰胺衍生物，并评估了它们的激酶抑制效力。在各种合成的酰胺中，化合物 20，一种环状酰胺/吡啶-2(1H)-one 衍生物，表现出与药物伊马替尼对抗 c-Src 激酶的 IC50 值相当，另一种化合物 (14) 含有 2- ((4-methyl-2-oxo-2H-chromen-6-yl)oxy) 乙酰胺的 IC50 值为 8.39 μM。此外，通过单晶X射线衍射技术证实了环酰胺衍生物的构成。这些结果可以作为开发新型下一代激酶抑制剂的途径。
• MORPHOLINYL AND PYRROLIDINYL ANALOGS
  申请人：Goodman Krista B.

  公开号：US20080021023A1

  公开（公告）日：2008-01-24

  The present invention relates to morpholinyl, and pyrrolidinyl analogs, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.

  本发明涉及吗吗啉基和吡咯啉基类似物，含有它们的药物组合物，以及它们作为尿苷II拮抗剂的用途。
• Development of Small-Molecule<i>Trypanosoma brucei N</i>-Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode
  作者：Daniel Spinks、Victoria Smith、Stephen Thompson、David A. Robinson、Torsten Luksch、Alasdair Smith、Leah S. Torrie、Stuart McElroy、Laste Stojanovski、Suzanne Norval、Iain T. Collie、Irene Hallyburton、Bhavya Rao、Stephen Brand、Ruth Brenk、Julie A. Frearson、Kevin D. Read、Paul G. Wyatt、Ian H. Gilbert

  DOI：10.1002/cmdc.201500301

  日期：2015.11

  bound in the previously reported active site, utilising a novel binding mode. This provides potential for further optimisation. The benzomorpholinone was also found to bind in a similar region. Using an X‐ray crystallography/structure‐based design approach, the benzomorpholinone series was further optimised, increasing activity against T. brucei NMT by >1000‐fold. A series of trypanocidal compounds were

  来自布氏锥虫的N-肉豆蔻酰转移酶(NMT)已在化学和生物学上被证实是人类非洲锥虫病的潜在药物靶点。我们之前报道了一些基于吡唑磺酰胺系列的非常有效的化合物的开发，这些化合物源自高通量筛选。在此，我们描述了在屏幕中也发现的噻唑烷酮和苯并吗啉支架的工作。大利什曼原虫中噻唑烷酮的 X 射线晶体结构NMT 利用一种新的结合模式显示了该化合物结合在先前报道的活性位点中。这提供了进一步优化的潜力。苯并吗啉酮也被发现在类似的区域结合。使用基于 X 射线晶体学/结构的设计方法，进一步优化了苯并吗啉酮系列，将抗布氏锥虫NMT 的活性提高了 1000 倍以上。确定了一系列具有合适体外 DMPK 特性的杀锥虫化合物，包括用于进一步开发的 CNS 暴露。需要进一步的工作来提高对人类 NMT 同种型的选择性和对布氏锥虫的活性。